Kamada Inks $50M Plasma Supply Deal with Leading Biopharma
KMDA is trading near its 52-week low of $6.5 (14% above the low).
Summary
Kamada signed a three-year agreement to supply normal source plasma from its Texas collection centers to a leading biopharmaceutical company, expecting approximately $50 million in revenue. Initial sales are slated for Q4 2026 and are already factored into the company's annual guidance. The deal validates Kamada's investment in its U.S. plasma collection infrastructure and supports its vertical-integration strategy. With a market cap around $407 million, the $50 million contract is a material revenue contributor. The company's Houston and San Antonio centers each have a planned capacity of 50,000 liters per year, indicating room for further supply agreements.
At the time of this announcement, KMDA was trading at $7.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $406.7M. The 52-week trading range was $6.50 to $9.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.